Exclusive: Top neuroscientist Asa Abeliovich targets ALS, schizophrenia with new startup Leal after $1B Lilly buyout

Af­ter strik­ing a bil­lion-dol­lar deal for his last start­up, Asa Abe­liovich has built a new ven­ture with even grander am­bi­tions in treat­ing some of the biggest neu­ro­log­i­cal dis­eases.

Abe­liovich ex­clu­sive­ly told End­points News about Leal Ther­a­peu­tics, his newest biotech that has op­er­at­ed in stealth for over two years. The Worces­ter, MA-head­quar­tered start­up raised a $39 mil­lion seed round in 2022, and is now rais­ing its next fi­nanc­ing to go in­to the clin­ic with its two lead drugs: LTX-001 in schiz­o­phre­nia and LTX-002 in ALS. The com­pa­ny plans to file IND ap­pli­ca­tions for both pro­grams in the sec­ond half of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.